Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Emily G. Hoffman"'
Autor:
Ninoschka C. D’Souza, Julian A. Aiken, Emily G. Hoffman, Sara C. Atherley, Sabrina Champsi, Nadia Aleali, Dorsa Shakeri, Maya El-Zahed, Nicky Akbarian, Mehran Nejad-Mansouri, Parinaz Z. Bavani, Richard L. Liggins, Owen Chan, Michael C. Riddell
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Elevated levels of somatostatin blunt glucagon counterregulation during hypoglycemia in type 1 diabetes (T1D) and this can be improved using somatostatin receptor 2 (SSTR2) antagonists. Hypoglycemia also occurs in late-stage type 2 diabet
Externí odkaz:
https://doaj.org/article/d6004c849ef2466b9d45505754e327f6
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Glucose homeostasis is primarily maintained by pancreatic hormones, insulin and glucagon, with an emerging role for a third islet hormone, somatostatin, in regulating insulin and glucagon responses. Under healthy conditions, somatostatin secreted fro
Externí odkaz:
https://doaj.org/article/718320647af546e7b81b09a913c81f75
Autor:
Emily G. Hoffman, Ninoschka C. D'Souza, Julian Aiken, Sara Atherley, Richard Liggins, Michael C. Riddell
Publikováno v:
Diabetes, Obesity and Metabolism. 25:1547-1556
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbd6f5c662081854f345dffaedfcdccc
https://doi.org/10.1111/dom.15002
https://doi.org/10.1111/dom.15002
Autor:
null Emily G. Hoffman, null Ninoschka C. D'Souza, null Julian Aiken, null Sara Atherley, null Richard Liggins, null Michael C. Riddell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7208554a9262f2a32181498d5004be28
https://doi.org/10.1111/dom.15002/v2/response1
https://doi.org/10.1111/dom.15002/v2/response1
Autor:
EMILY G. HOFFMAN, SARA C. ATHERLEY, NICKY AKBARIAN, NINOSCHKA DSOUZA, RICHARD LIGGINS, MICHAEL RIDDELL
Publikováno v:
Diabetes. 71
Background: Pancreatic islet remodelling in type 1 diabetes increases somatostatin (SST) expression, which inhibits glucagon counterregulation to hypoglycemia. Here, we characterized islet morphology and hormone composition in a rodent model of insul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d72bf67469b013b1c0267c9a3f3d630
https://doi.org/10.2337/db22-9-lb
https://doi.org/10.2337/db22-9-lb
Autor:
Aoibhe M. Pasieka, Richard Liggins, Owen Chan, Mahsa Jahangiriesmaili, Erin R. Mandel, Julian Aiken, Caylee A. Greenberg, Michael C. Riddell, Emily G. Hoffman, Ninoschka C. D’Souza, Trevor Teich
Publikováno v:
Endocrinology
Recent antecedent hypoglycemia is a known source of defective glucose counter-regulation in diabetes; the mechanisms perpetuating the cycle of progressive α-cell failure and recurrent hypoglycemia remain unknown. Somatostatin has been shown to suppr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc5ac8cf735bbd9a572f9721d5f122d
https://doi.org/10.1210/endocr/bqab189
https://doi.org/10.1210/endocr/bqab189
Publikováno v:
Diabetes. 70
Background: SSTR2a rescues glucagon counterregulation in type 1 diabetic rats. Here, we investigated its potential for resisting hypoglycemic onset in insulin-treated rats with T2D. Methods: T2D was induced in 8-9-week-old, male, Sprague-Dawley rats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::439f8de79697be6b1182ae1fbeccc974
https://doi.org/10.2337/db21-133-or
https://doi.org/10.2337/db21-133-or
Autor:
Emily G. Hoffman, Ninoschka C. D’Souza, Michael C. Riddell, Mariya Popkov, Sara C. Atherley, Richard Liggins, Sabrina Champsi
Publikováno v:
Diabetes. 70
Background: Defective glucagon counterregulation to hypoglycemia in T1D involves elevated somatostatin signalling on the α cell. In rats, SSTR2a treatment (ZT-01 Methods: High fat fed, low dose streptozotocin (T2D) and healthy rats were treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25faa2193791b36810a931ef2c2bfb14
https://doi.org/10.2337/db21-1197-p
https://doi.org/10.2337/db21-1197-p
Autor:
Julian Aiken, Michael C. Riddell, Mehran Nejad-Mansouri, Emily G. Hoffman, Richard Liggins, Ninoschka C. D’Souza, Parinaz Zaree Bavani
Publikováno v:
Diabetes. 68
Somatostatin Receptor 2 antagonists (SSTR2a) increase glucagon counter-regulation to hypoglycemia in various rodent models of type-1 diabetes mellitus. Here we investigated the efficacy of SSTR2a in improving glucagon counter-regulation in a rat mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a28c3e48c0d6ae626a3feac1970e6b
https://doi.org/10.2337/db19-14-lb
https://doi.org/10.2337/db19-14-lb